Acasti Pharma Debt to Equity Ratio 2014-2024 | GRCE
Current and historical debt to equity ratio values for Acasti Pharma (GRCE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Acasti Pharma debt/equity for the three months ending June 30, 2024 was 0.00.
| Acasti Pharma Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.01B |
$0.06B |
0.17 |
| 2024-03-31 |
$0.01B |
$0.06B |
0.19 |
| 2023-12-31 |
$0.01B |
$0.07B |
0.18 |
| 2023-09-30 |
$0.01B |
$0.07B |
0.17 |
| 2023-06-30 |
$0.01B |
$0.06B |
0.14 |
| 2023-03-31 |
$0.01B |
$0.07B |
0.16 |
| 2022-12-31 |
$0.02B |
$0.10B |
0.21 |
| 2022-09-30 |
$0.02B |
$0.10B |
0.21 |
| 2022-06-30 |
$0.02B |
$0.10B |
0.20 |
| 2022-03-31 |
$0.02B |
$0.11B |
0.19 |
| 2021-12-31 |
$0.00B |
$0.11B |
0.03 |
| 2021-09-30 |
$0.01B |
$0.11B |
0.05 |
| 2021-06-30 |
$0.01B |
$0.05B |
0.13 |
| 2021-03-31 |
$0.01B |
$0.06B |
0.12 |
| 2020-12-31 |
$0.01B |
$0.03B |
0.18 |
| 2020-09-30 |
$0.01B |
$0.01B |
0.56 |
| 2020-06-30 |
$0.01B |
$0.01B |
0.83 |
| 2020-03-31 |
$0.01B |
$0.01B |
0.76 |
| 2019-12-31 |
$0.03B |
$-0.01B |
-7.29 |
| 2019-09-30 |
$0.03B |
$-0.00B |
-23.66 |
| 2019-06-30 |
$0.03B |
$0.00B |
9.81 |
| 2019-03-31 |
$0.03B |
$0.01B |
2.34 |
| 2018-12-31 |
$0.02B |
$0.02B |
0.95 |
| 2018-09-30 |
$0.03B |
$-0.01B |
-2.34 |
| 2018-06-30 |
$0.02B |
$0.01B |
2.57 |
| 2018-03-31 |
$0.01B |
$0.01B |
1.79 |
| 2017-12-31 |
$0.01B |
$0.01B |
0.80 |
| 2017-09-30 |
$0.00B |
$0.01B |
0.33 |
| 2017-06-30 |
$0.00B |
$0.01B |
0.19 |
| 2017-02-28 |
$0.00B |
$0.02B |
0.18 |
| 2016-11-30 |
$0.00B |
$0.02B |
0.09 |
| 2016-08-31 |
$0.00B |
$0.02B |
0.07 |
| 2016-05-31 |
$0.00B |
$0.02B |
0.07 |
| 2016-03-31 |
$0.00B |
$0.02B |
0.07 |
| 2016-02-29 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
$0.02B |
0.07 |
| 2015-09-30 |
$0.00B |
$0.02B |
0.06 |
| 2015-06-30 |
$0.00B |
$0.03B |
0.09 |
| 2015-03-31 |
$0.00B |
$0.03B |
0.12 |
| 2014-12-31 |
$0.00B |
$0.03B |
0.10 |
| 2014-09-30 |
$0.01B |
$0.03B |
0.29 |
| 2014-06-30 |
$0.01B |
$0.03B |
0.24 |
| 2014-03-31 |
$0.01B |
$0.03B |
0.37 |
| 2014-02-28 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.01B |
$0.02B |
0.24 |
| 2013-09-30 |
$0.00B |
$0.02B |
0.18 |
| 2013-06-30 |
$0.00B |
$0.01B |
0.36 |
| 2013-03-31 |
$0.00B |
$0.01B |
0.25 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
